End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.089 AUD | +9.88% | +23.61% | +50.85% |
01:44am | Percheron Therapeutics Names Chief Medical Advisor | MT |
May. 29 | Percheron Therapeutics Completes Enrollment for Phase Two Muscular Dystrophy Trial; Shares Rise 3% | MT |
Business Summary
Number of employees: 8
Sales per Business
AUD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
ATL 1102
80.4
%
| 2 | 98.1 % | 2 | 80.4 % | -11.14% |
Unallocated
19.6
%
| 0 | 1.9 % | 0 | 19.6 % | +1,026.23% |
Sales per region
AUD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Australia
100.0
%
| 2 | 100.0 % | 2 | 100.0 % | +8.43% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
James Garner
CEO | Chief Executive Officer | - | 23-05-07 |
Phillip Hains
DFI | Director of Finance/CFO | 64 | 06-11-08 |
Anthony Filippis
COO | Chief Operating Officer | - | 22-10-31 |
Andrew McKenzie
PRN | Corporate Officer/Principal | - | - |
Alicia Mellors
SEC | Corporate Secretary | - | 21-02-23 |
George Tachas
PRN | Corporate Officer/Principal | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Phillip Hains
DFI | Director of Finance/CFO | 64 | 06-11-08 |
Ben Price
BRD | Director/Board Member | 68 | 21-10-03 |
James Garner
CEO | Chief Executive Officer | - | 23-05-07 |
Chairman | - | 21-03-21 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 901,544,971 | 754,230,363 ( 83.66 %) | 0 | 83.66 % |
Company contact information
Percheron Therapeutics Ltd.
Collins Place 35 Collins Street
3000, Melbourne
+61 3 9827 8999
http://www.PercheronTx.comSector
Sales per Business
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+50.85% | 48.49M | |
+13.99% | 118B | |
+12.39% | 106B | |
-4.32% | 24.28B | |
+1.14% | 21.96B | |
-9.35% | 18.16B | |
-42.28% | 16.37B | |
-18.34% | 15.56B | |
+3.83% | 13.63B | |
+27.28% | 12.27B |
- Stock Market
- Equities
- PER Stock
- Company Percheron Therapeutics Limited